Oncolytics: FDA Type D meeting in Aug; half of REO 033 sites activated, >20 patients pre-identified

ONCOLYTICS BIOTECH INC

Company to hold Type D meeting with FDA in first half of August 2026 to discuss registrational design for REO 033 Part B.
Approximately half of planned clinical sites for REO 033 Part A activated by end of July; more than 20 patients pre-identified.
Initial tumor response update from Part A expected by year-end 2026; Part B enrollment could begin Q1 2027 subject to FDA feedback.
Pelareorep has Fast Track designation from FDA for RAS-mutant MSS metastatic colorectal cancer.
Global lead PI Dr. Sanjay Goel opened enrollment at Rutgers Cancer Institute; remaining sites to be activated by end of August.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.